BioInvent International AB (STU:BIX) Total Stockholders Equity : €70.27 Mil (As of Mar. 2025)

View and export this data going back to 2013. Start your Free Trial

What is BioInvent International AB Total Stockholders Equity?

BioInvent International AB's Total Stockholders Equity for the quarter that ended in Mar. 2025 was €70.27 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. BioInvent International AB's Book Value per Share for the quarter that ended in Mar. 2025 was €1.07. The ratio of a company's debt over equity can be used to measure how leveraged this company is. BioInvent International AB's Debt-to-Equity for the quarter that ended in Mar. 2025 was 0.02.

BioInvent International AB Total Stockholders Equity Historical Data

The historical data trend for BioInvent International AB's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioInvent International AB Total Stockholders Equity Chart

BioInvent International AB Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Total Stockholders Equity

Get a 7-Day Free Trial

73.08

133.10

146.10

117.09

77.01

BioInvent International AB Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Total Stockholders Equity	Get a 7-Day Free Trial															108.92	97.22	88.36	77.01	70.27

BioInvent International AB (STU:BIX) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

BioInvent International AB's Book Value per Share for the quarter that ended in Mar. 2025 is

Book Value per Share	=	(Total Stockholders Equity	-	Preferred Stock)	/	Shares Outstanding (EOP)
	=	(70.267	-	0)	/	65.804
	=	1.07

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

BioInvent International AB's Debt-to-Equity for the quarter that ended in Mar. 2025 is

Debt-to-Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.837	+	0.55)	/	70.267
	=	0.02

BioInvent International AB Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of BioInvent International AB's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

BioInvent International AB Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioInvent International AB (STU:BIX) » Definitions » Total Stockholders Equity

Comparable Companies

Traded in Other Exchanges

BINV:Sweden 0H22:UK BIX0:Germany

Address

Ideongatan 1, Lund, SWE, SE-223 70

Website

https://www.bioinvent.com

BioInvent International AB is a clinical-stage biotech company. It discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapy, with currently four drug candidates in five ongoing clinical programs in Phase 1/2 trials for the treatment of hematological cancer and solid tumors, respectively. The company's validated, proprietary F.I.R.S.T technology platform identifies both targets and the antibodies that bind to them, generating many new drug candidates to fuel the company's clinical development pipeline and providing licensing and partnering opportunities. The company's pipeline portfolio comprises BI-1206, an antagonistic blocking antibody for the treatment of non-Hodgkin's lymphoma, and BI-1808 and BI-1910 (anti-TNFR2) for solid cancers.

BioInvent International AB Headlines

No Headlines